• Home
  • About Us
  • List of Health Insurance Companies

Health Plan News

Timely Health Plan News and Commmentary.

Health Plan News
Home Healthcare Plan News Douglas Pharmaceuticals announces results from Phase 2 trial of R-107 in subjects with Treatment Resistant Depression

Douglas Pharmaceuticals announces results from Phase 2 trial of R-107 in subjects with Treatment Resistant Depression

Posted on December 22, 2021 Written by Annalyn Frame

Douglas Pharmaceuticals Ltd (Douglas), a privately held New Zealand-headquartered pharmaceutical company, today announced positive top-line data from its multinational, randomized, placebo-controlled, double-blind Phase 2 study of R-107 designed to investigate the efficacy and safety of R-107 (ketamine 30, 60, 120 or 180 mg) versus placebo for TRD. The study was carried out in New Zealand and Australia, Singapore, Taiwan, and 2021. 168 patients were randomized.

TRD can be defined as the absence of clinically meaningful improvement in depression despite adequate doses at least two antidepressant drugs, administered for a reasonable duration and with good treatment adherence. TRD patients have limited treatment options.

Participants were subject to an open-label enrichment phase for one week. They received R-107 open label 120 mg/day for five days. Double-blind placebo was given to those who showed improvement in depression. They were randomly assigned to receive R-107 open-label 120 mg/day for 5 days. Primary endpoint was the change in depression ratings, Montgomery-Asberg Depression Rating Scales (MADRS).

The enrichment phase saw 73% (168/231) TRD patients quickly remit (MADRS score =12 within one week of open-label R-107 120mg daily treatment). During the enrichment phase, the mean MADRS scores dropped from 31 to 13.

Primary efficacy analysis revealed that 180 mg dosage group had a statistically significant reduction in MADRS score of 6.1 points compared to the placebo group (p=0.019). The MADRS score reductions in the 30 mg, 60mg, and 120m mg groups were 1.9, 0.75, and 4.5 points, respectively, as compared with placebo. These differences were not statistically significant.

R-107 was generally well tolerated. Headache, dizziness, anxiety were the most frequent TEAEs in all dose groups (>10% overall). The study did not report any product-related Serious Adverse Events.

Douglas plans to begin Phase 3 study in 2022 using the best dosing protocol as confirmed by Phase 2 studies.

Douglas Chief Scientific Officer Dr Peter Surman commented that he saw a clear dose-response relationship from the efficacy data. This makes it possible to select the optimal dosing protocol in the Phase 3 study. We are excited to move R-107 development into pivotal trials thanks to the compelling data of the BEDROC trial. This includes both the speed and durability of the response. We thank all the investigators who participated in the study, particularly for adapting to the Covid-19 pandemic. We look forward in continuing R-107 development with the goal to bring a new, effective treatment for the millions of TRD patients.

Jeff Douglas, Douglas’ Managing Director, stated that R-107 has “cleinically meaningful efficacy” as an anti-depressant, making it an ideal therapy for those who have suffered from TRD for many years without any relief. The quick recovery of mood within one week is a major advantage over current treatments, which can take up to six weeks.

Professor Paul Glue MD, University of Otago Hazel Buckland Professor and Chair of the Trial Steering Committee at BEDROC said, “As a researcher and a clinician who treats many patients suffering from TRD, these data are really encouraging.” R-107’s rapid onset of treatment response and its excellent tolerability compared to other methods of ketamine dosing is especially impressive. R-107, if confirmed in pivotal studies, could have a major impact on the way we treat patients with TRD.

R-107Douglas has been developing R-107, an oral treatment for depression that is fast acting. Ketamine is an antagonist of the NMDA receptor. R-107 has been formulated to release ketamine slowly and steadily over 12 hours. This helps to minimize psychotomimetic side-effects that can be associated with other ketamine dosage forms.

Phase 2 BEDROC study key results

Average total MADRS change from Day 1 through Day 92 vs. placebo group
R-107 180 mg group: 6.1, p=0.019
R-107 120 mg group: 4.5, p=0.083
R-107 60 mg group: 0.7, p=0.785
R-107 30 mg group: 1.9, p=0.450
Rapid-acting antidepressant action in enrichment phase (open label 120 mg daily).
73% (168/231) TRD subject responded to enrichment treatment with a MADRS score of =12, and a reduction of >=50% on Day 8.
The MADRS changes from Day 1 to Day 8 are 31 to 13, with a difference 18 (n=231)
Incidence of TEAEs in randomization phase (% patient):
R-107 180 mg group: 94%
R-107 120 mg group: 81%
R-107 60 mg group: 77%
R-107 30 mg group: 65%
Placebo group: 70%

Filed Under: Healthcare Plan News

Recent News

  • Numinus completes acquisition of Novamind June 13, 2022
  • NRx Pharmaceuticals Provides Update on Breakthrough Therapy Designation (BTD) Request for ZYESAMI® (aviptadil) June 13, 2022
  • King Insurance Acquires Wurzel Insurance June 13, 2022
  • Medicare Advantage Plans Earn High Marks in eHealth Survey June 13, 2022
  • Curated Mental Health Partners with Brooklyn Minds Psychiatry April 20, 2022
  • HEALTHWORXS: A Game Changer, No Cost Healthcare Plan April 20, 2022
  • Study Finds Consumers Want Their Physician to Lead April 20, 2022
  • Peer-Reviewed Journal Spotlights Lirio’s Approach to Behavioral Design and Its Ability to Impact Underserved Communities April 20, 2022
  • Braxia Scientific Provides Update on Clinical Trials for Ketamine and Psilocybin Drug Development February 8, 2022
  • Numinus Identified as a Licensed Psilocybin Supplier January 31, 2022

About Annalyn Frame

I am a nursing student currently, but have been interested in healthcare since I was much younger. It’s as if I have always known that I would eventually end up being a nurse or going into the healthcare industry.

I am the editor of Health Plan News.

Search Our Site

Ketamine Therapy Dallas
Ketamine Treatment Clinic Dallas

Categories

  • AARP
  • Aetna
  • AMERIGROUP
  • Blue Cross Blue Shield
  • Canadian Health Care System
  • Canadian Pharmacies
  • Cardinal Health
  • Chubb
  • CIGNA HealthCare
  • COVID-19
  • diabetes
  • Enterologics
  • Facilities And Providers
  • FDA
  • GlaxoSmithKline
  • Health Clinics
  • Health Insurance Coverage
  • Health Plan Enrollment
  • Healthcare Companies
  • Healthcare Plan News
  • HealthSouth
  • Home Care
  • Home Health Care Insurance
  • Hospitals
  • Humana
  • J.P. Morgan Healthcare Conference
  • Lidocaine
  • LifeTree eClinical
  • Lipitor
  • Liposuction
  • MedBasics
  • Medicaid
  • Medical And Healthcare
  • Medical Devices
  • Medicare
  • Mevion Medical Systems
  • Mobile Healthcare
  • Pharmaceutical Companies
  • Senior News
  • The SCOOTER Store
  • Thoracic Surgeons
  • thrombocytopenia
  • Today Sponge
  • Top Health Care Networks
  • Total Lumbar Fusion Graft Spine Surgery
  • Toxic Air Pollution
  • Trans Fats
  • Travel Insurance
  • Triglycerides
  • Tuberculosis
  • Unilife
  • United Healthcare
  • UnitedHealth Group
  • Unused Medications
  • Uterine fibroids
  • Vaccines
  • varicella
  • Ventas
  • Vyteris
  • WakeUpWalmart
  • Wal-Mart Healthcare Crisis
  • Walgreens Pharmacy
  • Water Quality
  • WebMD
  • WellPoint
  • West Nile Virus
  • Wilmer Shields Rich Awards
  • World Health Care Congress
  • Wound Management
  • Zelnorm
  • Zocor
  • ZOLOFT

Pages

  • 1199 National Benefit Fund
  • A Little about Drug Preparation and Formulation Development
  • About Us
  • Affordable Health Insurance
  • Benefits of Hiring a Senior Caregiving Service
  • Catastrophic Health Insurance
  • Cheap Health Insurance
  • Cheap Health Insurance Plans
  • Child Health Insurance Plans
  • Choosing a Health Insurance Plan
  • Christian Health Insurance
  • Dental Assistants and Their Future
  • Dr. Howard Bellin: Questions about Rhinoplasty
  • Finding the Right Dentist
  • Get Your Winks in Blink
  • Health Insurance
  • Health Insurance Plans For Family
  • Health Sharing Plans
  • Healthcare and Hospitals: Disinfection is Key
  • High Deductible Health Plans
  • Home Care Employment in Arizona
  • How A Medical Weight Loss Plan Can Help You Get The Figure You Want
  • How Ketamine Therapy Helps Fight Depression
  • How Orthotic Insoles Improve Your Health
  • Individual Health Insurance Plans
  • Ketamine Uses and Benefits
  • List of Health Insurance Companies
  • Low Income Health Insurance
  • Medical Research Consultants
  • Personal Lubricants for Women – Liven Up Your Life!
  • Private Health Insurance Plans
  • Rhesus Negative
  • Self Employed Health Insurance
  • Short Term Health Insurance Plans
  • Student Health Insurance Plans
  • Temporary Health Insurance
  • The Basic Building Blocks For a Sustained, Healthy Diet
  • The Importance of Clinical Study Software
  • The Use of Post Cycle Therapy Supplements
  • Travel Health Insurance

Copyright © 2022 · Focus Pro Theme on Genesis Framework · WordPress · Log in

Go to mobile version